Navigation Links
Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
Date:11/28/2008

AMSTERDAM, Nov. 28 /PRNewswire/ -- Oncology focused biopharmaceutical company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR(TM), a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease (GvHD) for end stage leukemia patients. Under the agreement Professor Velardi will continue the development on the selective depletion of allo-reactive T cells from mismatched donors using Kiadis Pharma's ATIR(TM). Kiadis Pharma is preparing for a multi-center pivotal study on ATIR(TM) to start early 2009 and Professor Velardi will participate in this upcoming study.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, who is a leader in the field of mismatched bone marrow transplantations," says Dr. Manja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients."

Professor Andrea Velardi says: "So far, we have treated 25 blood cancer patients who have received bone marrow from mismatched donors, including donor immune cells that are selectively depleted of cells causing acute Graft versus Host Disease using the ATIR(TM) process. The results so far are promising and I am therefore very pleased to continue to work with Kiadis Pharma in this field."

For the complete press release please go to: www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different p
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 The new research ... (High & Medium), Sub-type (Primary & Secondary), and ... & Transportation & Power Generation) - Trends and ... market with analysis and forecasting of the market ... Tables with 52 Figures spread through 146 Pages ...
(Date:10/27/2014)... NEW YORK , Oct. 27, 2014 ... in the recent Ebola concern in the ... for the virus.  The healthcare market researcher said the ... of in vitro diagnostic tests for the detection of ... sensitivity has proved useful.  Kalorama routinely assess the IVD ...
(Date:10/27/2014)... Called the NOAH Protocol, this investigative ... of pediatric brain cancer. The implications for groundbreaking ... years of research and development. Amber Larkin, the ... mom's determination can make a difference. , ... it’s only fitting that we’ve received FDA approval ...
(Date:10/27/2014)... Pa. , Oct. 27, 2014 ... Foundation of America (CCFA) announced today the launch ... , an educational campaign designed to ... diseases (IBD) on the paired role of nutrition ... To view the multimedia assets associated with this ...
Breaking Biology Technology:Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4
... 2011 Although top bio-pharmaceutical companies agree that Key ... of a new product, increasing competition has made it ... the role of Medical Science Liaisons (MSLs) in forging ... recent years. In fact, today, ...
... YORK, March 21, 2011 Reportlinker.com announces that ... its catalogue: Global Nanobiotechnology Industry ... This report analyzes the worldwide markets for Nanobiotechnology ... - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials ...
... China PharmaHub Corp. (OTC Bulletin Board: CPHB ... that it has signed a exclusive worldwide license agreement ... develop, commercialize and market a universal donor blood product ... Professor of Medicine and Pediatrics Dr. Ewa Carrier. The ...
Cached Biology Technology:Newly Updated for 2011: Medical Science Liaison Study Shows Growth in KOL Outreach, Impact 2Reportlinker Adds Global Nanobiotechnology Industry 2Reportlinker Adds Global Nanobiotechnology Industry 3Reportlinker Adds Global Nanobiotechnology Industry 4Reportlinker Adds Global Nanobiotechnology Industry 5Reportlinker Adds Global Nanobiotechnology Industry 6Reportlinker Adds Global Nanobiotechnology Industry 7Reportlinker Adds Global Nanobiotechnology Industry 8Reportlinker Adds Global Nanobiotechnology Industry 9Reportlinker Adds Global Nanobiotechnology Industry 10Reportlinker Adds Global Nanobiotechnology Industry 11Reportlinker Adds Global Nanobiotechnology Industry 12Reportlinker Adds Global Nanobiotechnology Industry 13Reportlinker Adds Global Nanobiotechnology Industry 14Reportlinker Adds Global Nanobiotechnology Industry 15Reportlinker Adds Global Nanobiotechnology Industry 16Reportlinker Adds Global Nanobiotechnology Industry 17China PharmaHub In-Licenses Universal Donor Red Blood Cells Technology Exclusively From University of California, San Diego 2
(Date:10/29/2014)... As bodies decompose, their types and numbers of ... provide could mean the difference between a closed ... University is using a more than $866,000 U.S. ... investigators examine these changing populations. The microbial communities ... of death, gender, race, socioeconomic relations and more, ...
(Date:10/29/2014)... — Cambridge, MA and Hebei, China — BGI Tech ... quality sequencing of the Jujube genome. Jujube is the ... the Jujube genome is particularly difficult to sequence due ... It is the first time that a genome in ... has been recently published in Nature Communications ...
(Date:10/29/2014)... kidney cancer patients in Europe sheds light on the ... apparent link between exposure to aristolochic acid and incidence ... by an international team led by scientists from the ... underscores the importance of investigating possible sources of exposure ... the Aristolochia genus, also has been suspected of causing ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3
... in Clive Svendsen,s lab dishes, he couldn,t have been ... type lost in patients with the devastating neurological disease ... Wisconsin-Madison stem cell biologist had recreated the hallmarks of ... derived from a patient. By allowing scientists the ...
... genes that control the handedness of snail shells, and they ... humans to set up the left and right sides of ... publication in Nature by University of California, Berkeley, ... establishing the left-right asymmetry of animals for 500-650 million years, ...
... Thirteen UC Riverside researchers have been named fellows of ... Including this years fellows, the total number of UCR ... distinction is 172., Election as a fellow is an ... year AAAS gave this honor to 486 of its ...
Cached Biology News:Patient-derived induced stem cells retain disease traits 2Patient-derived induced stem cells retain disease traits 3Snails and humans use same genes to tell right from left 2Snails and humans use same genes to tell right from left 3Snails and humans use same genes to tell right from left 413 UCR faculty members recognized by American Association for the Advancement of Science 213 UCR faculty members recognized by American Association for the Advancement of Science 3
Chlamydia pneumoniae (TWAR)...
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Mouse monoclonal [CP23] to Ricin communis ( Abpromise for all tested applications)....
... Antibody - Red, 20X ... antibody at 20X concentration for use ... assays. Quality Assurance ... FarRed fluorescence polarization assays. ...
Biology Products: